Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Born after 1968~* Good general health~* Available for the duration of the trial~Exclusion Criteria:~* Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease~* Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study~* Liver, renal, or hematologic disease~* Alcohol or drug abuse within 12 months of study entry~* History of severe allergic reaction or anaphylaxis~* Current asthma or reactive airway disease~* History of Guillain-Barre syndrome~* HIV-1 infected~* Hepatitis C virus infected~* Positive for hepatitis B surface antigen (HBsAg)~* Known immunodeficiency syndrome~* Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical corticosteroids are not excluded.~* Live vaccine within 4 weeks of study entry~* Killed vaccine within 2 weeks of study entry~* Absence of spleen~* Blood products within 6 months of study entry~* Current smoker~* Have traveled to the Southern Hemisphere or Asia within 30 days prior to study entry~* Have traveled on a cruise ship within 30 days prior to study entry~* Work in the poultry industry~* Investigational agents within 60 days prior to study entry, or currently participating in another investigational vaccine or drug trial~* Allergy to eggs or egg products~* Purified protein derivative (PPD) positive (positive tuberculosis \[TB\] test)~* Family member with immunodeficiency~* Other condition that, in the opinion of the investigator, would affect the participant's participation in the study~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops.
- 2 (Type: EXPERIMENTAL): One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).